Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study

Published:2019-09-03 Issue:4-5 Volume:20 Page:111-122
ISSN:2578-7489
Container-title:HIV Research & Clinical Practice
language:en
Short-container-title:HIV Research & Clinical Practice

Author:

Murray Miranda¹,Pulido Federico²,Mills Anthony³,Ramgopal Moti⁴,LeBlanc Roger⁵,Jaeger Hans⁶,Canon Viviam⁷,Dorey David⁸,Griffith Sandy⁹^ORCID,Mrus Joseph⁹,Spreen William⁹,Margolis David⁹

Affiliation:

1. ViiV Healthcare, London, UK;

2. Hospital Universitario 12 de Octubre, UCM, (imas12), Madrid, Spain;

3. Southern California Men’s Medical Group, West Hollywood, CA, USA;

4. Midway Immunology and Research Center, Fort Pierce, FL, USA;

5. Immunodeficiency Service Division of Hematology, Royal Victoria Hospital, McGill University Health Centre, Montreal, Quebec, Canada;

6. HIV Research and Clinical Care Centre, MUC Research GmbH and MVZ Karlsplatz, Munich, Germany;

7. Division of Janssen Pharmaceutica NV, Janssen Research & Development, Beerse, Belgium;

8. GlaxoSmithKline, Mississauga, Ontario, Canada;

9. ViiV Healthcare, Research Triangle Park, NC, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Infectious Diseases

Link

https://www.tandfonline.com/doi/pdf/10.1080/25787489.2019.1661696

Reference14 articles.

1. The Survival Benefits of AIDS Treatment in the United States

2. Simplification of antiretroviral therapy: a necessary step in the public health response to HIV/AIDS in resource-limited settings

3. Long-acting antiviral agents for HIV treatment

4. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early Implementation and Outcomes Among People with HIV Who Accessed Long-Acting Injectable Cabotegravir/Rilpivirine at Two Ryan White Clinics in the U.S. South;AIDS Research and Human Retroviruses;2024-07-16

2. Consensus recommendations for use of long‐acting antiretroviral medications in the treatment and prevention of HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07

3. Factors associated with patient satisfaction with antiretroviral therapy in Japan: A cross-sectional, multicenter study;Journal of Infection and Chemotherapy;2024-02

4. Acceptability of Switching to Long-Acting Cabotegravir and Rilpivirine Among People Living with HIV on Dolutegravir/Rilpivirine Combination: A Single-Center Experience;AIDS Research and Human Retroviruses;2023-10-23

5. Factors Associated with Preferences for Long-Acting Injectable Antiretroviral Therapy Among Adolescents and Young People Living with HIV in South Africa;AIDS and Behavior;2023-01-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3